|
|
 |
Registry of Lobbyists - Kelly Grover
To find further information on a company or organization check the Registry of Joint Stock Companies
|
|
| Registration Number | Status | | | 1443 | Inactive | | | Initial registration date | Last date of any changes | | 1-June-2016 | 23-October-2018 |
|
Senior Officer's Last Name
Grover |
Senior Officer's First Name
Kelly
|
Middle Initial
|
|
Business Address of Senior Officer
Cystic Fibrosis Canada |
City
Toronto |
Province/State
ON |
Country
CA |
Postal/Zip Code
M4P 2C9 |
Telephone
4164859149 |
Fax
|
| |
Name of Organization
Cystic Fibrosis Canada |
Registry of Joint Stock Companies Number
|
Business Address of Lobbyist's Business or Firm
2323 Yonge Street, Suite 800 |
City
Toronto |
Province/State
ON |
Country
CA |
Postal/Zip Code
M4P2C9 |
Telephone
4164859149 |
Fax
|
|
| Employee Name |
|
| John Wallenburg |
View |
| Kim Steele |
View |
| Joanna Vaslamis |
View |
| Lisa Weatherhead |
View |
| Eric Mariglia |
View |
| Kelly Grover |
View |
|
|
|
|
|
Description of Organization:
Cystic Fibrosis Canada is a national charitable not-for-profit corporation established in 1960, and is one of the world’s top three charitable organizations committed to finding a cure for cystic fibrosis (CF). As an internationally recognized leader in funding innovation and clinical care, we invest more in life-saving CF research and care than any other non-governmental agency in Canada. |
|
Description of Membership:
We are a registered charity with between 50-100 staff. Our head office is in Toronto and we have regional directors throughout the country, as well as volunteers.
We have a board of directors, who can be found here: http://www.cysticfibrosis.ca/about-us/board-of-directors-and-senior-team.
Our senior leadership staff members can be found here: http://www.cysticfibrosis.ca/about-us/staff-directory
|
|
|
|
|
| Description |
|
| We have informed the Ministry of Health about a new CF drug, lumacaftor/ivacaftor (Orkambi), which we hope will be funded by the provincial drug plan.
|
View |
| We will urge the Ministry of Health to fund lumacaftor/ivacaftor. We will encourage constituents to arrange one on one meetings with their MLAs and to write to their government representatives. CF Canada will also be meeting with elected officials to share information and our recommendations regarding lumacaftor/ivacaftor.
In addition, we are advocating for a pan-Canadian rare disease strategy as part of a national pharmacare program, through which a nation-wide definition of rare disease and a process for evaluating drugs for rare disease should be implemented.
We are also encouraging the Government of Nova Scotia to improve the transition of care for people with CF who move from paediatric clinic to adult clinic, in addition to calling for improved mental health services. |
View |
|
|
| Funding Government Name |
Funding Amount |
|
| Government of British Columbia |
230000 |
View |
|
|
No private funding related to lobbying activities
|
|
|
|
|
